NRx Pharmaceuticals (NASDAQ:NRXP) Announces Earnings Results, Beats Estimates By $0.16 EPS

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.16, Zacks reports.

NRx Pharmaceuticals Stock Performance

Shares of NRXP traded down $0.04 during trading hours on Monday, hitting $2.15. 726,308 shares of the stock were exchanged, compared to its average volume of 1,113,704. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $5.05. The company has a market cap of $93.84 million, a price-to-earnings ratio of -3.91 and a beta of 2.11. The stock’s 50-day moving average price is $2.82 and its two-hundred day moving average price is $2.96.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NRXP shares. BTIG Research boosted their price objective on NRx Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 11th. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Tuesday, November 3rd. Wolfe Research began coverage on shares of NRx Pharmaceuticals in a research note on Thursday, October 15th. They issued an “outperform” rating on the stock. Finally, Zacks Research downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 26th. Six equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Read Our Latest Stock Report on NRXP

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.

Read More

Earnings History for NRx Pharmaceuticals (NASDAQ:NRXP)

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.